🇺🇸 FDA
Patent

US 12226373

Treatment of fragile X syndrome with cannabidiol

granted A61KA61K31/658A61K36/185

Quick answer

US patent 12226373 (Treatment of fragile X syndrome with cannabidiol) held by Harmony Biosciences Management, Inc. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Harmony Biosciences Management, Inc.
Grant date
Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/658, A61K36/185, A61K9/0014, A61K9/06